FNDC5(跨膜蛋白Ⅲ型纤连蛋白结构域5,fibronectin typeⅢdomain-containing protein 5),也称为纤连蛋白III型重复蛋白含蛋白(FRCP2)和过氧化物酶体蛋白(Pep),在2002年由两个独立的实验室分别发现并命名,研究显示该蛋白可在骨骼肌,心脏...FNDC5(跨膜蛋白Ⅲ型纤连蛋白结构域5,fibronectin typeⅢdomain-containing protein 5),也称为纤连蛋白III型重复蛋白含蛋白(FRCP2)和过氧化物酶体蛋白(Pep),在2002年由两个独立的实验室分别发现并命名,研究显示该蛋白可在骨骼肌,心脏和大脑中表达。2012年的一项研究揭示了FNDC5的裂解和作用形式,并将其裂解形成的分泌结构域命名为Irisin(鸢尾素)。自Irisin被发现在体内有各种生理作用,引起了世界各地研究人员的兴趣,并得到了广泛的研究,文章综述重点介绍Irisin的结构、表达、功能及其与肿瘤发生发展相关的作用。展开更多
Irisin is a myokine that is generated by cleavage of the membrane protein fibronectin type Ⅲ domain-containing protein 5(FNDC5) in response to physical exercise. Studies reveal that irisin/FNDC5 has neuroprotective f...Irisin is a myokine that is generated by cleavage of the membrane protein fibronectin type Ⅲ domain-containing protein 5(FNDC5) in response to physical exercise. Studies reveal that irisin/FNDC5 has neuroprotective functions against Alzheimer's disease, the most common form of dementia in the elderly, by improving cognitive function and reducing amyloid-β and tau pathologies as well as neuroinflammation in cell culture or animal models of Alzheimer's disease. Although current and ongoing studies on irisin/FNDC5 show promising results, further mechanistic studies are required to clarify its potential as a meaningful therapeutic target for alleviating Alzheimer's disease. We recently found that irisin treatment reduces amyloid-β pathology by increasing the activity/levels of amyloid-β-degrading enzyme neprilysin secreted from astrocytes. Herein, we present an overview of irisin/FNDC5's protective roles and mechanisms against Alzheimer's disease.展开更多
文摘FNDC5(跨膜蛋白Ⅲ型纤连蛋白结构域5,fibronectin typeⅢdomain-containing protein 5),也称为纤连蛋白III型重复蛋白含蛋白(FRCP2)和过氧化物酶体蛋白(Pep),在2002年由两个独立的实验室分别发现并命名,研究显示该蛋白可在骨骼肌,心脏和大脑中表达。2012年的一项研究揭示了FNDC5的裂解和作用形式,并将其裂解形成的分泌结构域命名为Irisin(鸢尾素)。自Irisin被发现在体内有各种生理作用,引起了世界各地研究人员的兴趣,并得到了广泛的研究,文章综述重点介绍Irisin的结构、表达、功能及其与肿瘤发生发展相关的作用。
基金supported by Cure Alzheimer’s Fund (to RET and SHC)JPB Foundation (to RET),and R56AG072054 (to SHC)。
文摘Irisin is a myokine that is generated by cleavage of the membrane protein fibronectin type Ⅲ domain-containing protein 5(FNDC5) in response to physical exercise. Studies reveal that irisin/FNDC5 has neuroprotective functions against Alzheimer's disease, the most common form of dementia in the elderly, by improving cognitive function and reducing amyloid-β and tau pathologies as well as neuroinflammation in cell culture or animal models of Alzheimer's disease. Although current and ongoing studies on irisin/FNDC5 show promising results, further mechanistic studies are required to clarify its potential as a meaningful therapeutic target for alleviating Alzheimer's disease. We recently found that irisin treatment reduces amyloid-β pathology by increasing the activity/levels of amyloid-β-degrading enzyme neprilysin secreted from astrocytes. Herein, we present an overview of irisin/FNDC5's protective roles and mechanisms against Alzheimer's disease.
